Research Project: Myeloperoxidase Promotes Persistent Fibrosis
Grant Awarded:
Dalsemer Grant
Research Topic:
basic biologic mechanisms
Research Diseases:
interstitial lung disease
pulmonary fibrosis
Pulmonary fibrosis (PF) is a progressive fatal lung disease expected to increase dramatically due to post-COVID complications. In human disease and experimental models, it remains unclear what separates normal wound healing from progressive lung scarring and persistent disease. An enzyme called myeloperoxidase increases in PF and has been correlated with rapid deterioration of pulmonary fibrosis patients. Myeloperoxidase contributes to fibrosis in other major organ systems as well. Whether myeloperoxidase contributes to PF progression and prevents resorption of scar tissue is unknown. We will use laboratory tests and animal models of PF to determine the role of this enzyme in PF and determine if it is a potential target for treatment.
Join over 700,000 people who receive the latest news about lung health, including research, lung disease, air quality, quitting tobacco, inspiring stories and more!
Thank you! You will now receive email updates from the American Lung Association.